RecruitingPhase 1NCT07295847

A Study of AZD0120 in Autoimmune Diseases

A Phase 1b, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases


Sponsor

AstraZeneca

Enrollment

27 participants

Start Date

Jan 9, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new investigational drug called AZD0120 in people with autoimmune diseases — conditions where the body's immune system mistakenly attacks its own tissues. **You may be eligible if...** - You have been diagnosed with an autoimmune disease - You are in adequate overall health as determined by medical evaluation - You can follow the required medication washout period before starting the study - You are able to give informed consent **You may NOT be eligible if...** - You have serious underlying health problems that could make participation unsafe - You are currently taking medications that cannot be stopped before the study - You are pregnant or breastfeeding - Specific autoimmune conditions or disease severity levels that the study excludes (as determined by the study team) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAZD0120

CD19/BCMA Autologous CAR T-cell therapy product


Locations(18)

Research Site

Tucson, Arizona, United States

Research Site

Stanford, California, United States

Research Site

Chicago, Illinois, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

St Louis, Missouri, United States

Research Site

New York, New York, United States

Research Site

Chapel Hill, North Carolina, United States

Research Site

Seattle, Washington, United States

Research Site

Darlinghurst, Australia

Research Site

Waratah, Australia

Research Site

Hamburg, Germany

Research Site

Mainz, Germany

Research Site

Würzburg, Germany

Research Site

Barcelona, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Edinburgh, United Kingdom

Research Site

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07295847


Related Trials